Below are answers to the most frequent questions from prescribers like you, categorized by indication and key topic areas. If your questions are not covered on this page or you need additional information, please let us know. We’ll contact you by your preferred method—email, mail, or phone.

References: 1. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35-46. 2. Markvardsen LH, Debost JC, Harbo T, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013. doi: 10.1111/ene.12080. 3. Berger M. Subcutaneous IgG in neurologic diseases. Immunotherapy. 2014;6(1):71-83.
You are now leaving the current website.

Do you want to continue?

No Yes